Financial Comparison: Adamas Pharmaceuticals (ADMS) vs. Its Competitors

Adamas Pharmaceuticals (NASDAQ: ADMS) is one of 194 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Adamas Pharmaceuticals to related companies based on the strength of its institutional ownership, valuation, analyst recommendations, earnings, profitability, dividends and risk.

Earnings & Valuation

This table compares Adamas Pharmaceuticals and its peers revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Adamas Pharmaceuticals $570,000.00 -$60.05 million -8.54
Adamas Pharmaceuticals Competitors $220.75 million -$39.68 million -63.16

Adamas Pharmaceuticals’ peers have higher revenue and earnings than Adamas Pharmaceuticals. Adamas Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Adamas Pharmaceuticals and its peers, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Adamas Pharmaceuticals 0 0 7 0 3.00
Adamas Pharmaceuticals Competitors 504 2398 6494 122 2.65

Adamas Pharmaceuticals presently has a consensus price target of $42.00, indicating a potential upside of 45.88%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.39%. Given Adamas Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Adamas Pharmaceuticals is more favorable than its peers.


This table compares Adamas Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Adamas Pharmaceuticals N/A -68.00% -53.83%
Adamas Pharmaceuticals Competitors -3,485.68% -115.20% -39.05%

Volatility and Risk

Adamas Pharmaceuticals has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500. Comparatively, Adamas Pharmaceuticals’ peers have a beta of 1.55, meaning that their average stock price is 55% more volatile than the S&P 500.

Institutional & Insider Ownership

70.6% of Adamas Pharmaceuticals shares are held by institutional investors. Comparatively, 48.7% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 29.0% of Adamas Pharmaceuticals shares are held by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.


Adamas Pharmaceuticals beats its peers on 7 of the 12 factors compared.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc. is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues. It has developed a portfolio of chrono-synchronous therapies to address chronic neurologic disorders. Its first product candidate is ADS-5102, a chrono-synchronous amantadine therapy, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). It has completed Phase II proof-of-concept study of ADS-5102 in these patients. Its Phase III clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. Its second product candidate is ADS-4101, an extended-release version of single-agent compound for the treatment of epilepsy (partial onset seizures).

Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply